SCHEMBL5633501

SCHEMBL5633501

C[C@@H](NC(=O)Nc1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCN(C)C2=NC#N)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 5/20 0.57
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 2/20 0.37
CNR1 P21554 2/20 0.37
TSHR P16473 1/20 0.37
NLRP3 Q96P20 1/20 0.37
RAB9A P51151 2/20 0.36
USP30 Q70CQ3 1/20 0.36
NPC1 O15118 1/20 0.36
CCR1 P32246 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
FPR1 P21462 1/20 0.35
FPR2 P25090 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5633494 1.00 F10 (0.57) F10MAPTSMN1; SMN2LMNAMEN1
SCHEMBL5633314 0.90 F10 (0.46) F10MAPTSMN1; SMN2LMNAHTT
SCHEMBL5633316 0.90 F10 (0.46) F10MAPTSMN1; SMN2LMNAHTT
SCHEMBL5633543 0.88 F10 (0.49) F10SMN1; SMN2FPR2
SCHEMBL5633540 0.88 F10 (0.49) F10SMN1; SMN2FPR2
SCHEMBL5630439 0.86 EP300 (0.46) F10MAPTCNR1ALDH1A1FPR2
SCHEMBL5631602 0.86 F10 (0.60) F10MAPTSMN1; SMN2CNR1USP30
SCHEMBL5631603 0.86 F10 (0.60) F10MAPTSMN1; SMN2CNR1USP30
SCHEMBL5630444 0.86 EP300 (0.46) F10MAPTCNR1ALDH1A1FPR2
SCHEMBL5632819 0.84 HTT (0.41) F10MAPTSMN1; SMN2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183277-B2 Alpha-((aryl or heteroaryl)ureido or carbamoyloxy)-N-heteroaryl amides; blood-coagulation factor Xa and VIIa inhibitors; synergistic mixtures with other antitumor agents or anticoagulants MERCK PATENT GMBH (DE) 2007-02-27 US claimed
US-20050171154-A1 Carboxylic acid amides MERCK PATENT GMBH (DE) 2005-08-04 US claimed
US-7183277-B2 Alpha-((aryl or heteroaryl)ureido or carbamoyloxy)-N-heteroaryl amides; blood-coagulation factor Xa and VIIa inhibitors; synergistic mixtures with other antitumor agents or anticoagulants MERCK PATENT GMBH (DE) 2007-02-27 US disclosed
US-20050171154-A1 Carboxylic acid amides MERCK PATENT GMBH (DE) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171154-A1 Carboxylic acid amides F11, F12, F2 F10 4/4885MAPT 4346/4885SMN1; SMN2 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.